MRI and Gene Expression in Diagnosing Patients with Ductal Breast Cancer In Situ
This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. MRI may help find and diagnose patients with breast cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. Genetic studies may help doctors predict the outcome of treatment and the risk for disease recurrence. Performing MRI with genetic studies may help determine the best treatment for patients with breast cancer in situ.
Information about the study from ECOG/ACRIN
This important trial funded by DCP is open and actively accruing new participants. More specific information can be found in the links below.
Preventing High-Risk Adenomas and Second Cancers in Colon Cancer Survivors (S0820)
In this trial, people who have undergone curative surgery for stage 0-3 colon cancer, with or without adjuvant chemotherapy, will be randomly assigned to take sulindac and a placebo, eflornithine and a placebo, both sulindac and eflornithine, or two placebo pills for 36 months. Doctors will closely monitor all trial participants throughout the study to detect the recurrence of high-risk adenomas or the development of new colon or rectal cancers.
The Division of Cancer Prevention is expanding clinical research beyond standard trial designs to find interventions that may play a role in more than one prevalent disease.
Using Non-Cancer Trials to Find Cancer Prevention Signals
Diabetes Prevention Program Outcome Study (DPPOS) Collaboration with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCI is looking at this cohort study to examine if metformin or lifestyle intervention used to prevent development of diabetes in a population at risk of the disease, can also modify cancer incidence, especially in obesity-related cancers (breast, colon & rectum, endometrium, pancreas, esophagus, gall bladder, and kidney).
Aspirin in Reducing Events in Elderly (ASPREE) Study Collaboration with the National Institute on Aging (NIA)
Aspirin in Reducing Events in the Elderly (ASPREE) is a Phase III double-blind, randomized, placebo-controlled primary prevention trial designed to assess whether daily active treatment of 100 mg enteric-coated aspirin would extend the duration of disability-free life in healthy participants aged 70 years, and aged 65 and above for Hispanic and African Americans in the USA. The study was examining whether the potential benefits of low-dose aspirin outweigh the risks in this age group.
On June 14, 2017, the NIA concluded that it was extremely unlikely that the study would show benefit from aspirin for the primary outcome: a life free of dementia and disability. The study included19,114 participants from the U.S. and Australia (2,411 in the US and 16, 703 in Australia). NCI is funding the collection of biospecimens from this randomized trial and is looking into cancer incidence and mortality in the study group. Long-term follow up will continue in a study called ASPREE-XT.
Primary results on dementia and disability, mortality, and cardiovascular disease were published on September 16, 2018 in the New England Journal of Medicine. Results of the cancer outcomes are expected in 2019.
- Daily low-dose aspirin found to have no effect on healthy life span in older people NIH News Release, posted 09/16/2018
- Aspirin in Reducing Events in the Elderly (ASPREE) from NIA
- ASPREE Website links (U.S. and Australian site information
- ASPREE Intervention Ended, June 2017
- ASPREE Study protocol on clinicaltrials.gov